Tracer library / [131I]I-131-Lym-1
[131I]I-131-Lym-1
Also written as I-131-Lym-1
- Radionuclide
- I-131 t½ 11549 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 0
What it is
- Compound class
- radiolabeled antibody (radioimmunoconjugate)
- Target / mechanism
- Lym-1 antibody target (HLA-DR-like B-cell surface antigen) PMID 9406709
- Clinical application
- Patients with B-cell non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) with splenomegaly PMID 9406709
- Theranostic pair
- —
Published syntheses
No synthesis has been parsed for this agent yet.
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.2007 · Cancer Biother Radiopharm · Retrospective
- Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients.1999 · Nucl Med Biol · Clinical study
- Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies.1997 · Clin Cancer Res · Clinical study
Need this precursor?We can point you to suppliers for [131I]I-131-Lym-1, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 5 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage 26: this agent has NO own synthesis/characterisation data in the current corpus -- its only linked run(s) were unlinked (empty-quote recheck: appeared only as a control/comparator or in the wrong article).